FGFR2 genotype and risk of radiation-associated breast cancer in Hodgkin lymphoma

Blood

Volumn 119, Issue 4, 2012, Pages 1029-1031

  Ma, Yussanne P ^a   Van Leeuwen, Flora E ^b   Cooke, Rosie ^a   Broeks, Annegien ^b   Enciso Mora, Victor ^a   Olver, Bianca ^a   Lloyd, Amy ^a   Broderick, Peter ^a   Russell, Nicola S ^b   Janus, Cecile ^c   Ashworth, Alan ^d   Houlston, Richard S ^a   Swerdlow, Anthony J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d Breakthrough Breast Cancer Research Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALLELE; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; FEMALE; FGFR2 GENE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; NETHERLANDS; PRIORITY JOURNAL; RADIATION HAZARD; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED KINGDOM;

EID: 84863041217     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-10-383380     Document Type: Article

References (26)

1. van Leeuwen FE, Swerdlow AJ, Travis LB. Second cancers after treatment of Hodgkin lymphoma. In: Hoppe RT, Mauch PT, Armitage JO, Diehl V, Weiss LM, eds. Hodgkin Lymphoma. Philadelphia, PA: Wolters Kluwer, Lippincott Williams & Wilkins; 2007;347-370.
2. Hodgson DC, van Leeuwen FE. Second malignancy risk after treatment of Hodgkin lymphoma. In: Engert A, Horning SJ, eds. Hodgkin Lymphoma. Berlin Heidelberg, Germany: Springer-Verlag; 2011;305-331.
3. De Bruin ML, Sparidans J, van't Veer MB, et al. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. J Clin Oncol. 2009;27(26):4239-4246.
4. Gatti RA. The inherited basis of human radiosensitivity. Acta Oncol. 2001;40(6):702-711. (Pubitemid 33081978)
5. Burrill W, Barber JB, Roberts SA, Bulman B, Scott D. Heritability of chromosomal radiosensitivity in breast cancer patients: a pilot study with the lymphocyte micronucleus assay. Int J Radiat Biol. 2000;76(12):1617-1619.
6. Thomas G, Jacobs KB, Kraft P, et al. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet. 2009;41(5):579-584.
7. Stacey SN, Manolescu A, Sulem P, et al. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet. 2007;39(7): 865-869. (Pubitemid 47014497)
8. Ahmed S, Thomas G, Ghoussaini M, et al. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet. 2009;41(5):585-590.
9. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007; 447(7148):1087-1093. (Pubitemid 47014426)
10. Fletcher O, Johnson N, Orr N, et al. Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study. J Natl Cancer Inst. 2011;103(5):425-435.
11. Stacey SN, Manolescu A, Sulem P, et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet. 2008;40(6):703-706. (Pubitemid 351748861)
12. Gold B, Kirchhoff T, Stefanov S, et al. Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc Natl Acad Sci U S A. 2008;105(11):4340-4345. (Pubitemid 351754382)
13. Zheng W, Long J, Gao YT, et al. Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat Genet. 2009; 41(3):324-328.
14. Enciso-Mora V, Broderick P, Ma Y, et al. A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3). Nat Genet. 2010;42(12):1126-1130.
15. Turner N, Lambros MB, Horlings HM, et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene. 2010; 29(14):2013-2023.
16. Haugsten EM, Wiedlocha A, Olsnes S, Wesche J. Roles of fibroblast growth factor receptors in carcinogenesis. Mol Cancer Res. 2010;8(11):1439-1452.
17. Meyer KB, Maia AT, O'Reilly M, et al. Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol. 2008;6(5): e108.
18. Matsubara A, Teishima J, Mirkhat S, et al. Restoration of FGF receptor type 2 enhances radiosensitivity of hormone-refractory human prostate carcinoma PC-3 cells. Anticancer Res. 2008;28(4B): 2141-2146.
19. Diller L, Medeiros Nancarrow C, Shaffer K, et al. Breast cancer screening in women previously treated for Hodgkin's disease: a prospective cohort study. J Clin Oncol. 2002;20(8):2085-2091. (Pubitemid 34408799)
20. Howell SJ, Searle C, Goode V, et al. The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage. Br J Cancer. 2009; 101(4):582-588.
21. Ramsey J, Birrell G, Lavin M. Breast cancer and radiotherapy in ataxia-telangiectasia heterozygote. Lancet. 1996;347(9015):1627. (Pubitemid 26170891)
22. Offit K, Gilad S, Paglin S, et al. Rare variants of ATM and risk for Hodgkin's disease and radiation-associated breast cancers. Clin Cancer Res. 2002;8(12):3813-3819. (Pubitemid 35424774)
23. Broeks A, Russell NS, Floore AN, et al. Increased risk of breast cancer following irradiation for Hodgkin's disease is not a result of ATM germline mutations. Int J Radiat Biol. 2000;76(5):693-698. (Pubitemid 30345171)
24. Bhatia S, Meadows AT, Robison LL, Late Effects Study Group. Family history of patients with breast cancer after treatment of Hodgkin's disease in childhood. Lancet. 1997;350(9081):888-889. (Pubitemid 27404368)
25. Hill DA, Gilbert E, Dores GM, et al. Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factors. Blood. 2005;106(10):3358-3365. (Pubitemid 41609165)
26. Broderick P, Cunningham D, Vijayakrishnan J, et al. IRF4 polymorphism rs872071 and risk of Hodgkin lymphoma. Br J Haematol. 2009;148(3): 413-415.